Analytical Results Highlight Efficacy of AnaSpec MOG Peptides

July 25, 2007 – San Jose, CA

Reporting on results gathered from its antibody and assay kit departments, AnaSpec has released data that supports the efficacy of its MOG(35-55) peptide.

Analytical results reported the following:

AnaSpec’s mouse/rat MOG(35-55) peptide induced EAE in C57BL/6 mice with 100% incident (10/10). These results provide quantitative support for the suitability of the MOG peptide for in vivo EAE study. Experimental autoimmune encephalomyelitis (EAE) is an in vivo animal model for multiple sclerosis (MS) pathogenesis.

AnaSpec’s mouse/rat MOG(35-55) peptide induced anti-MOG(35-55) autoantibody production in C57BL/6 mice with 100% incident (10/10). These results provide quantitative support for the suitability of the MOG peptide for in vivo anti-MOG(35-55) autoantibody study.

AnaSpec’s mouse/rat MOG(35-55) peptide induced polyclonal anti-MOG(35-55) antibody production in rabbits with high specificity, high affinity, and high titer (>3125K) indicating the high purity of AnaSpec’s MOG peptide as well as suitability for peptide-coated ELISA and Western blot assay.

Using AnaSpec’s mouse/rat MOG(35-55) peptide as a coating peptide, AnaSpec produced the industry’s first anti-MOG (35-55) ELISA kit for EAE study. The detection limit was measured to be as low as 50 pg of anti-MOG (35-55) autoantibody in serum or cerebrospinal fluid. After testing different lots of AnaSpec MOG peptides for ELISA coating, AnaSpec reported that the quality variation from lot to lot was minimal.

Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry. Established in 1993, AnaSpec's headquarters and manufacturing facilities are located in San Jose, CA.

For more information visit www.anaspec.com